User:Mr. Ibrahem/Eflapegrastim

Eflapegrastim, sold under the brand names Rolvedon, is a medication used to reduce the risk of febrile neutropenia in non-myeloid cancers receiving chemotherapy that results in bone marrow suppression. It is given by injection under the skin. It is given about 24 hours after chemotherapy.

Common side effects include tiredness, nausea, diarrhea, pain, fever, rash, and low red cells. Other side effects may include spleen rupture, ARDS, anaphylaxis, low platelets, glomerulonephritis, and myelodysplastic syndrome. It is a granulocyte colony-stimulating factor (G-CSF), specifically a leukocyte growth factor.

Eflapegrastim was approved for medical use in the United States in 2022. It is not approved in Europe or the United Kingdom as of 2022. It costs about 4,700 USD per dose in the United States as of 2022.